Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
——

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's share-based payment award options outstanding - number?
Supernus Pharmaceuticals (SUPN) reported share-based payment award options outstanding - number of 6.8M in Q1 2026.
How has Supernus Pharmaceuticals's share-based payment award options outstanding - number changed year-over-year?
Supernus Pharmaceuticals's share-based payment award options outstanding - number decreased by 11.5% year-over-year, from 7.6M to 6.8M.
What is the long-term trend for Supernus Pharmaceuticals's share-based payment award options outstanding - number?
Over 2 years (2023 to 2025), Supernus Pharmaceuticals's share-based payment award options outstanding - number has grown at a -1.8% compound annual growth rate (CAGR), from 6.6M to 6.3M.
What does share-based payment award options outstanding - number mean?
This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.